New paradigms in the prevention of ASCVD: The role of EPA and triglycerides

The benefits of icosapent ethyl in addressing residual risk: What is the evidence?

The benefits of icosapent ethyl in addressing residual risk What is the evidence

Subtitles available:  English, German, French & more

Media formats available:
  • Overview

    Despite CV risk reduction with LDL-c control with statins, there is a high percentage residual CV risk. Three speakers discuss the players in residual risk with a focus on triglycerides. Additionally, they present data of the REDUCE-IT trial with icosapent ethyl and provide guidance for implementation of icosapent ethyl in the management of patients with residual risk.

    This course consists of 3 episodes. Watch all episodes, answer pre- and post-test questions, and start earning CME credits.

  • Program Highlights

    This educational program consists of three presentations on EPA and triglycerides.

    Reassessing the role of triglycerides in residual cardiovascular risk - Richard Hobbs, MD – Oxford, UK

    • Richard Hobbs talks about the global burden of CVD, CVD risk factors, and the role of triglycerides in residual CV risk.

    The benefits of icosapent ethyl in addressing residual risk: What is the evidence? - Lale Tokgözoğlu, MD – Ankara, Turkey

    • Lale Tokgözoğlu provides an overview of studies that investigated the effects of omega-3 fatty acids with a focus on icosapent ethyl.

     Integrating icosapent ethyl in preventive strategies: Practical guidance - Victor Aboyans, MD, PhD – Limoges, France

    • The REDUCE-IT trial demonstrated the efficacy of icosapent ethyl to reduce CV events in patients with elevated triglycerides and high CV risk. Victor Aboyans discusses how to implement icosapent ethyl in clinical practice.
  • Instructions

    • Watch the three lectures and answer the pre- and post-test questions
    • Fill in the evaluation questions
    • Download CME Certificate

    For questions regarding this activity, please contact us at

  • Learning Objectives

    • Describe the factors related to residual risk
    • Compare the findings from large trials with omega-3 fatty acids
    • Recall the recommendations in the guidelines with regard to icosapent ethyl
    • Discuss the safety of icosapent ethyl
  • Target Audience

    This educational activity is designed for all healthcare professionals with an interest in management of patients with residual risk.

  • Accreditation and Credit Designation Statements

    This online course is accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC) for 1 hour of external CME credit.

    Through an agreement between EBAC and the American Medical Association, physicians may convert EBAC External CME credits to AMA PRA Category 1 Credits™. Information on the process to convert EBAC credit to AMA credit can be found on the AMA website. Other health care professionals may obtain from the AMA a certificate of having participated in an activity eligible for conversion of credit to AMA PRA Category 1 Credit™.

  • Commercial Support

    Funding for this educational program was provided by an unrestricted educational grant received from Amarin.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of PACE-cme.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments


We’re glad to see you’re enjoying PACE-CME…
but how about a more personalized experience?

Register for free